Guardant Health (NASDAQ:GH – Get Free Report) will release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Guardant Health to post earnings of ($0.57) per share for the quarter. Guardant Health has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.
Guardant Health (NASDAQ:GH – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.94). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The business had revenue of $168.49 million for the quarter, compared to analysts’ expectations of $150.51 million. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Guardant Health Stock Up 2.9 %
Shares of NASDAQ GH opened at $36.29 on Wednesday. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $41.06. The firm’s 50-day simple moving average is $29.52 and its 200 day simple moving average is $23.55. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Guardant Health
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Stories
- Five stocks we like better than Guardant Health
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- Why is the Ex-Dividend Date Significant to Investors?
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.